Myelodysplastic syndrome (MDS) resulting from a clonal stem cell is a heterogeneous
disease that complicates therapeutic decisions. Most patients are of advanced age with
attendant comorbities, making treatment choices difficult. Current treatment options include
bone marrow transplant, which appears to be the only curative option, and supportive care.
In elderly patients, risks for transplant are high and supportive-care treatments are
ineffective. However, considerable progress has been made in understanding the pathology …